Registration Dossier

Administrative data

Description of key information

Acute toxicity - oral

Available acute toxicity values for the Azacyclonol are:

 - LD50oral 650 mg/kg (mouse)

 - LD50oral 984 mg/kg (rat/male)

- LD50oral >1000 mg/kg (rat/female)

 

During the acute oral toxicity study where doses administered were 750, 1000 and 1300 mg/kg, (i) no mortality was recorded among the females (1000 mg/kg), (ii) in males, mortality was 100%, 60% and 0% in the 1300, 1000 and 750 mg/kg dose-groups, respectively. Mortality occurred between day 2 and day 8.

 

According to the 1272/2008 CLP regulation, the substance is classified as Acute Tox.4; H302 (harmful if swallowed (LD50between 300 < categoria 4 ≤ 2 000)).

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Referenceopen allclose all

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: OECD, GLP study
Reference:
Composition 0
Qualifier:
according to
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Version / remarks:
This type of study is no longer part of the OECD guidelines for the Testing of Chemicals
GLP compliance:
yes
Test type:
standard acute method
Test material information:
Composition 1
Specific details on test material used for the study:
solid - liquid: suspension

- Name of test material (as cited in study report): Azacyclonol-Base
- Physical state: whitish granular powder
- Purity: 98.3 % (w/w)
- Impurities (identity and concentrations): included in the certificate of analysis
- Batch No.: 86000298
- Storage conditions: at +4°C and protected from Iight
- Date of receipt: 31 October 1997
- A certificate of analysis is included in the report.
Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Iffa Crédo, Domaine des Oncins, 69210 L’Arbresle, France
- Number and sex: Two males and two females were used for the preliminary test and three groups of five males and/or five females each for the main test.
- Age at initiation of treatment: 6 weeks
- Weight at initiation of treatment: Male: 182 ± 8 g; Female: 149 ± 10 g
- Fasting period before study: Food was withdrawn 18 hours before dosing and redistributed approximately 4 hours after administration of the test substance.
- Housing: housed in polycarbonate cages (48 cm x 27 cm x 20 cm). 4 to 7 animals of the same sex during the acclimatization period and 5 rats of the same sex during the treatment period. Each cage contained dust-free sawdust (SICSA).
- Diet (e.g. ad libitum): controlled pelleted rodent diet (AO4 C, U.A.R.) ad libitum.
- Water (e.g. ad libitum): filtered by a F.G. Millipore membrane (0.22 micron)
- Acclimatization period: 5 days before treatment

ENVIRONMENTAL CONDITIONS
- Temperature: 21 ± 2 ° C
- Relative Humidity: 30 to 70%
- Ventilation: 12 cycles/hour of filtered, non-recycled air
- Light/dark cycle: 12/12 hours
Route of administration:
oral: gavage
Vehicle:
other: 0.5% methylcellulose aqueous solution
Details on oral exposure:
VEHICLE
- Concentration in vehicle: Suspension in a 0.5% methylcellulose aqueous solution
- Administration volume: 10 mL/kg
Doses:
Preliminary study: 1000 and 2000 mg/kg
Main study: 750, 1000 and 1300 mg/kg
No. of animals per sex per dose:
Preliminary study: 2 rats/sex/dose
Main study: 5 rats/males/dose and 5 females rats for 1000 mg/kg
Control animals:
other:
Details on study design:
- Treatment frequency: Once, a single administration on day 1 (D1)
- Duration of observation period following administration: 15 days
- Frequency of observations and weighing:
= Clinical signs: daily observations
= Body weight (D1, 8, 15)
- Necropsy of survivors performed: yes at D15
Statistics:
The 70 to 95 % confidence interval limits were calculated statistically according to Fieller's method ( 1944).
Preliminary study:
At the 2000 mg/kg dose-level: animals died on day 1 or 2; sedation or hypoactivity, tremors and piloerection were noted prior to death.
At the 1000 mg/kg dose-level: sedation or hypoactivity, tremors, dyspnoea and piloerection were observed in both animals on days 1 and 2. No mortality occurred. Recovery was complete on day 3.
Key result
Sex:
male
Dose descriptor:
LD50
Effect level:
>= 984 mg/kg bw
Based on:
not specified
Remarks on result:
other: Determination of LD50 with 70% confidence interval limits
Key result
Sex:
female
Dose descriptor:
LD50
Effect level:
> 1 000 mg/kg bw
Based on:
not specified
Mortality:
No mortality was recorded among the females (1000 mg/kg).
In males, mortality was 100%, 60% and 0% in the 1300, 1000 and 750 mg/kg dose-groups, respectively. Mortality occurred between day 2 and day 8.
Clinical signs:
At 1300 mg/kg dose-level: hypoactivity, piloerection and tremors in all males from day 1. Dyspnoea, sedation and lateral recumbency in one animal prior to death.
At 1000 mg/kg dose-level: Sedation or hypoactivity, tremors and piloerection in all animals on day 1; lateral recumbency in one animal. Hypoactivity and piloerection persisted in the surviving animals on day 2; recovery was complete on day 3.
At 750 mg/kg dose-level:hypoactivity, tremors and piloerection in all animals on day 1; dyspnoea in one animal between day 2 and day 5. No other clinical signs and no mortality were noted.
Body weight:
No treatment-related changes for females (1000 mg/kg).
Body weight gain of the treated males given 1000 or 750 mg/kg was reduced between day 1 and day 8 compared to historical control values; it returned to normal thereafter.
Gross pathology:
No treatment-related changes.
Interpretation of results:
Category 4 based on GHS criteria
Conclusions:
The LD50 determined experimentally was 984 mg/kg in male. Toxicity was lower in females, concentration level of 1000 mg/kg bw did not induce any adverse effects. According to the 1272/2008 CLP regulation, the substance is classified category 4 for acute oral toxicity.
Executive summary:

According to the 1272/2008 CLP regulation, the substance is classified category 4 for acute oral toxicity.

Endpoint:
acute toxicity: oral
Type of information:
other: RTECS
Adequacy of study:
other information
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
other: Secondary source
Reference:
Composition 0
Test material information:
Composition 1
Species:
mouse
Route of administration:
oral: unspecified
Key result
Sex:
not specified
Dose descriptor:
LD50
Effect level:
> 650 mg/kg bw
Interpretation of results:
Category 4 based on GHS criteria
Conclusions:
Azacyclonol has a LD50 = 650 mg/kg in mouse. According to the 1272/2008 CLP regulation, the substance is classified category 4 for acute oral toxicity.
Executive summary:

Azacyclonol has a LD50 = 650 mg/kg in mouse. According to the 1272/2008 CLP regulation, the substance is classified category 4 for acute oral toxicity.

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
LD50
984 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

Justification for classification or non-classification

Acute toxicity - oral

According to the 1272/2008 CLP regulation, the substance is classified as Acute Tox.4; H302 (harmful if swallowed (LD50between 300 < categoria 4 ≤ 2 000)).